Search results
Showing 3751 to 3800 of 4138 results for patient
These are the main stages in the multiple technology appraisal process used before April 2018.
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the cost comparison appraisal
Agenda and papers of the NICE public board meeting on 21 September 2023
Agenda and papers of the NICE public board meeting on 11 December 2024
A step-by-step timeline of the process we used to develop single technology appraisals (STA).
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
Tools for building or evaluating a medtech evidence base with NICE
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country
using the expertise of the royal medical colleges, professional bodies and patient/carer organisations. 2002 First clinical guideline...
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
The principles that guide the development of NICE guidance and standards.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Read NICE's statement on modern slavery and human trafficking.
NICE's past research and projects
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
Read NICE's patient and public involvement policy.
A step-by-step summary about how we develop our technology appraisal guidance.
NICE's partners
Our role in the Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
NICE priority methodological research areas.
We assess the value of digital health technologies that offer the greatest potential to improve health and wellbeing.
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
learn more about how decisions are made, incorporating the role of the patient voice. Our guests are Kay Nolan, head of prioritisation...
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
NICE guidance and standards support health professionals by providing evidence-based recommendations that enhance clinical decision-making and patient care.
People can comment on our guidance at specific stages in its development.
Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.
Making a positive impact: people and communities network case studies
Making a positive impact: NICE people and communities network case studies
We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.
Four AI technologies conditionally recommended to help detect undiagnosed fragility fractures
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
people whose care is covered by the quality standard (for example user, patient, carer, charity and other non-governmental...
Involving you in the development of NICE guidance.
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.
Join NICE's people and communities network
We want you to help NICE to develop our guidance for NHS and care services.
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Referral points to virtual wards are similar to traditional models of care. Our guidance and advice can help you decide where to provide care and what to consider.